Yartemlea (narsoplimab-wuug) for Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy
Customize your policy alerts
Sign up for Bluecross Idaho Policy MP 5.01.677 alerts
Get alerted when Policy MP 5.01.677 changes without checking for updates manually.
Monitor payer policy activity
This policy governs medical-necessity and prior-authorization requirements for intravenous Yartemlea in adults and children at least 2 years old with hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). It specifies diagnostic confirmation, documentation, specialist involvement, dosing, quantity limits, and continuation-response requirements.
Blue Cross of Idaho added a new policy addressing intravenous Yartemlea (narsoplimab-wuug) for hematopoietic stem cell transplant-associated thrombotic microangiopathy.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.